Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Acta Haematol. 2011;126(2):63-7. doi: 10.1159/000324799. Epub 2011 Apr 7.
A 55-year-old woman with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia (ATL) and a history of previously treated Strongyloides stercoralis infection received anti-CD52 monoclonal antibody therapy with alemtuzumab on a clinical trial. After an initial response, she developed ocular involvement by ATL. Alemtuzumab was stopped and high-dose corticosteroid therapy was started to palliate her ocular symptoms. Ten days later, the patient developed diarrhea, vomiting, fever, cough, skin rash, and a deteriorating mental status. She was diagnosed with disseminated S. stercoralis. Corticosteroids were discontinued and the patient received anthelmintic therapy with ivermectin and albendazole with complete clinical recovery.
一位 55 岁女性患有人类 T 细胞嗜淋巴细胞病毒 1 型(HTLV-1)相关成人 T 细胞白血病(ATL),并曾患有已治疗的粪类圆线虫感染。她参加了一项临床试验,接受了抗 CD52 单克隆抗体药物阿仑单抗治疗。在最初有反应后,她出现了 ATL 的眼部受累。阿仑单抗被停用,开始使用大剂量皮质类固醇治疗来缓解她的眼部症状。10 天后,患者出现腹泻、呕吐、发热、咳嗽、皮疹和精神状态恶化。她被诊断为播散性粪类圆线虫感染。停用了皮质类固醇,患者接受了伊维菌素和阿苯达唑驱虫治疗,临床完全康复。